OpenEvidence, an AI-driven platform designed to assist doctors in diagnosing and treating patients, has successfully raised $200 million in funding, achieving a valuation of $6 billion. The platform utilizes advanced technology similar to ChatGPT to enhance medical decision-making and improve patient outcomes.

AI is not a panacea for medical progress, particularly in the fight against diseases like Alzheimer’s. While it has potential to enhance drug design and improve diagnostics, significant bottlenecks in understanding disease mechanisms, trial participation, and public health initiatives still require attention and funding beyond AI capabilities. Investments in biomedical science and public health are essential for achieving meaningful advancements in medicine.

Assort Health has secured $76 million in Series B funding to enhance its AI-driven patient experience platform, Assort OS, aiming to simplify healthcare interactions such as scheduling appointments and managing prescriptions. The company leverages agentic AI to reduce patient wait times and improve access to care, addressing long-standing frustrations in the healthcare system. With this funding, Assort Health plans to expand its team and further develop its technology to streamline operations for healthcare providers.

Assort Health has secured $26 million in funding to enhance its AI platform designed for managing patient phone calls, aiming to improve healthcare access by reducing wait times and scheduling inaccuracies. The technology has already driven significant revenue growth and high patient satisfaction, demonstrating its potential to transform healthcare operations.